E Therapeutics (ETX)

 
Due to recent changes by the London Stock Exchange relating to MiFID II, some AIM stocks are trading off‑book and therefore not showing recent prices, price changes or trades. We are working with the LSE to improve this situation.

ETX Share PerformanceMore

52 week high13.2500 22/06/17
52 week low6.0000 01/06/17
52 week change 1.0000 (11.94%)
4 week volume36,910,743 29/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

e-Therapeutics unveils board changes

e-Therapeutics has announced the appointment of Christine Soden as non-executive director, and the retirement of Brad H...

Appointment of Director

RNS Number: 1796V e-Therapeutics plc 01 November 2017 e-Therapeutics ('e-Therapeutics' or the 'Company') Appointment of Director Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine Soden as non-executive ...

Edison issues update on e-Therapeutics (ETX)

Edison Investment Research Limited Edison issues update on e-Therapeutics (ETX) 05-Oct-2017 / 11:34 GMT/BST London, UK, 5 October 2017 Edison issues update on e-Therapeutics (ETX) e-Therapeutics' (ETX) interim numbers demonstrate tight cost control and focus on the rationalised pipeline, with continued investment into the Network-Driven Drug Discovery pla...

Interim Results for 6 Months Ended 31 July 2017

RNS Number: 7667R e-Therapeutics plc 26 September 2017 e-Therapeutics ('e-Therapeutics' or the 'Company') Interim Results for the 6 Months Ended 31 July 2017 Executing Against Plan with Reduced Loss and Lower Cash Burn Oxford, UK, 26 September 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) t...

e-therapeutics schedules interims

e-therapeutics will announce its results for the six months ended 31 July on 26 September. At 9:47am: (LON:ETX) eTherapeu...

Notice of Results

RNS Number: 8457P e-Therapeutics plc 05 September 2017 E-THERAPEUTICS PLC ("e-therapeutics" or the "Company") Notification of Half Year Results Date Oxford, UK - 5 September 2017 - e-therapeutics plc (AIM: ETX), a company using Network-Driven Drug Discovery (NDD) to create new and better drugs, will announce its half year results for the six month...

Director Deals - e-Therapeutics PLC (ETX)

Iain Ross, Chairman, bought 250,000 shares in the company on the 22nd August 2017 at a price of 10.60p. The Director now...

Director Deals - e-Therapeutics PLC (ETX)

Iain Ross, Chairman, bought 250,000 shares in the company on the 22nd August 2017 at a price of 10.60p. The Director now...

Fundamental DataMore

EPS-4.91
Dividend yield0 %

Latest discussion posts More

  • Q1 2017 blog update - ETX

    Q1 2017 blog weekly ETX chart update - notes under each chart: http://bonker99.com/Blogs
    10-Feb-2017
    Bonker
  • ETX chart

    http://bonker99.com/charts
    6-Feb-2017
    Bonker
  • Results

    RNS available at company's website. although seems to be missing in III ...
    22-Mar-2016
    nk1999

Users' HoldingsMore

Users who hold E Therapeutics also hold..
LLOYDS GRP.29%
ROCKHOPPER29%
RANGE RES.25%
PREMIER OIL20%
VODAFONE GRP.20%

Codes & Symbols

ISINGB00B2823H99
SymbolsETX, LSE:ETX, ETX.L, ETX:LN, LON:ETX, XLON:ETX

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account